Key Targets and Future Market Potential of Ubiquitin

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Key Targets and Future Market Potential of Ubiquitin Enzymes 2016-2030

Dublin, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report to their offering. The "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report provides an extensive study on the current landscape of the evolving pipeline of ubiquitin enzyme inhibitors and offers a comprehensive discussion on the future potential of this market.

The ubiquitin proteasome system (UPS) is one of the key protein degradation pathway involved in the control of protein homeostasis and turnover that mediates the regulation of several cellular processes. The UPS consists of two separate consecutive steps, ubiquitination and proteasomal degradation. Due to its involvement in multiple metabolic and regulatory functions, the UPS is considered as a vital part of the cellular machinery controlling protein homeostasis.

Ubiquitin enzymes have been implicated in various cellular processes, such as protein homeostasis, apoptosis, autophagy, DNA damage repair, cell cycle control and senescence. Due to their involvement in multiple metabolic and regulatory functions, any deviations in the normal functioning of the UPS has been shown to lead to the development of diverse types of diseases. Initial research on the UPS led to the development of several proteasome inhibitors, such as Velcade®, Kyprolis® and Ninlaro®, which are already available in different regions across the globe. However, since these drugs target the entire protein degradation pathway, lack of target specificity renders them potentially harmful and their use has been shown to pose side effects in patients. Consequently, the focus is gradually shifting from proteasome inhibitors to targeting specific components of the UPS, primarily on ubiquitination enzymes. This is a relatively new segment of the overall market. With no marketed products, the UPS associated enzyme inhibitors/modulators market is still in its infancy. The report primarily focuses on four classes of enzymes that have been shown to possess therapeutic relevance; these include E1 activating enzymes, E2 conjugating enzymes, E3 ligases and deubiquitinases (DUBs). Among other elements, the report provides the following information: - The current state of the market with respect to the key players, phase of development of pipeline products (both clinical and preclinical/discovery), target enzyme classes and the key disease indications. - Comprehensive profiles highlighting clinical trial details, key preclinical/clinical findings and future market opportunity for the clinical stage (phase I/II, phase II and phase III) ubiquitin enzyme inhibitors. - Various investments and grants received by companies focused in this area in order to accelerate and support their R&D activities. - Partnerships that have taken place in the recent past covering product development/commercialization agreements, research collaborations, clinical trial collaborations, license agreements, acquisitions and other such deals between stakeholders in the industry. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Ubiquitin Enzyme Inhibitors: Market Overview 5. Key Insights: Therapeutic Areas and Potential Targets 6. E1 and E2 Enzymes as Therapeutic Targets 7. E3 Enzymes as Therapeutic Targets 8. DUB Enzymes as Therapeutic Targets 9. Associated Drug Classes 10. Venture Capital Interest 11. Recent Collaborations 12. Market Forecast and Opportunity Analysis 13. Conclusion 14. Interview Transcripts 15. Appendix 1: Tabulated Data 16. Appendix 2: List Of Companies And Organizations

Companies Mentioned - 3SBio - 5AM Ventures - ARCH Venture Partners - Abbiotec - Abcam - AcelRx Pharmaceuticals - Aegera Therapeutics - Aeneas Ventures - Agilis Biotherapeutics - Aileron Therapeutics - Aju IB Investment - Alexion Pharmaceuticals - Almac Discovery - Amgen - Angelman Syndrome Foundation - Apeiron Biologics - Apple Tree Partners - Arcus Ventures - Argenta Discovery - Argos Soditic - Arvinas - Ascenta Therapeutics - Ascentage Pharma - Astellas Venture Management - Astex Pharmaceuticals - AstraZeneca - Australasian Leukemia and Lymphoma Group - Avacta - BPS Biosciences - Bavarian Research Foundation - Bio-Techne - BioTheryx - Biogen - Biogenova - Biotechnology and Biological Sciences Research Council - Boehringer Ingelheim - Boston Biochem - Boston University Technology Development... - BostonBiochem - Business Development Bank of Canada - Business Development Corporation (BDC) Capital - C4 Therapeutics - CMEA Ventures - Calculus Capital - Canaan Partners - Cancer Research Technology - Captor Therapeutics - Carmot Therapeutics - Cayman Chemicals - Celgene Corporation - Cell Signaling Technology - CellCentric - CellXplore - Cellivery Therapeutics - Celon Laboratories - Chinese University of Hong Kong - Cisbio Bioassays - Clarus Ventures - Cleave Biosciences - Cobro Ventures - Columbia University - Comprehensive Cancer Center of Wake Forest University - Connecticut Innovations - Cormorant Asset Management - Curis - Cyclofluidic - Daiichi Sankyo - Dana-Farber Cancer Institute - Debiopharm - Desjardins Venture Capital - Deutsche Bank - Domain Associates - Dr. Reddy's - Draper Esprit - Draper Fisher Jurvetson - E3X Bio - EG Capital Group - Edmond de Rothschild Investment Partners - Elan Pharmaceuticals - Elm Street Ventures - Encycle Therapeutics - Endeavour Vision - Ensemble Therapeutics - Enterprise Partners - Enzo Lifesciences - Erimos Pharmaceutical - Excel Venture Management - F-Prime Capital Partners - Flagship Ventures - Focus Biomolecules - Forma Therapeutics - Foundation Venture Capital Group - Foundation for Angelman Syndrome Therapeutics (FAST) - Fox Chase Cancer Center - Francis Crick Institute - Genentech (Hoffmann-La Roche) - GlaxoSmithKline - GrowthWorks Capital - Halle University - Harris & Harris Group - Harvard Medical School - Hasso Plattner Ventures - Hatteras Venture Partners - HealthCare Ventures - Horizon Discovery - Human Genome Sciences - Hybrigenics - IP Group - Imperial Innovations - Index Ventures - Innovate UK - Intrexon - Invenio Therapeutics - Investissement Québec - Janssen Research & Development - Kamiya Biomedical Company - Karolinska Institute - Laboratorio Varifarma - Latterell Venture Partners - Life Technologies - LifeSensors - Ligand Pharmaceuticals - Lilly Ventures - Linköping University - Lurie Investment Fund - MVM Life Science Partners - MaRS Investment Accelerator Fund - Majuven - Makoto Life Sciences - Mayo Clinic - Medical Research Council - Memorial Sloan Kettering Cancer Center - Merck - Meso Scale Discovery - MiRx Pharmaceuticals - Michael J. Fox Foundation - Millennium Pharmaceuticals - Miltenyi Biotec - Mission Therapeutics - Morningside Venture Investments - Mount Sinai Hospital's Lunenfeld-Tanenbaum Research Institute - Multiple Capital - Natco Pharma - National Cancer Institute - National Institutes of Health Small Business Innovation Research - New Enterprise Associates - New Leaf Venture Partners - New York University - Nextech Invest - Novartis Pharmaceuticals - Novitas Capital - Novus Biologics - Nurix - Nxt2b - Ono Pharmaceutical - Onyx Pharmaceuticals - OrbiMed - Osage University Partners - Oxford Bioscience Partners - Parkwalk Advisors - Peloton Therapeutics - Penn Pharmaceutical Services - PerkinElmer - Perrigo Company - Perseus - Pfizer - Pharmascience - Pharmion Corporation - Priaxon - Progenra - Promega - Proteologics - Proteostasis Therapeutics - Proteros Biostructures - Providence Investment Company - Quaker BioVentures - Queen's University - R & D Systems - RA Capital Management - Remeditex Ventures - Rigel Pharmaceuticals - Roche - Roswell Park Cancer Institute - SR One - SV Life Sciences - Sanofi - Sanofi-Genzyme BioVentures - Santa Cruze Biotech - Scottish Investment Bank (Investment Arm of Scottish Enterprise) - Selleckchem - Sequoia Capital - Servier - Sidney Kimmel Comprehensive Cancer Center - Sigma-Aldrich - Sofinnova Ventures - Statsyuk Research Group - Stemgent - Supergen - Taiho Pharmaceutical - Takeda - Tensha Therapeutics - TetraLogic Pharmaceuticals - The Column Group - Thermo Fisher Scientific - Thiel Foundation's Breakout Labs - Third Rock Ventures - Tocris - Tokyo Medical University - UBP Biotech - UbiQ Therapeutics - Ubiquigent - Universities of Toronto and Sherbrooke - University of Birmingham - University of Cambridge Enterprise - University of Delaware - University of Dundee - University of Florida - University of Glasgow - University of Liverpool - University of Michigan - University of Oxford - University of Rome Tor Vergata - University of South Florida (USF) - University of Texas - University of Toronto - Université de Montréal - VenGrowth Capital Partners - Vivolux - Walter and Eliza Hall Institute of Medical Research - Woodford Patient Capital Trust - Wren Capital - Yale University - Yonsei University College of Medicine - Yorkville Advisors For more information about this report visit http://www.researchandmarkets.com/research/4p4bfp/ubiquitin

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Enzymes

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 101

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 49

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 91

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 177

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 121

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 95

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 108

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 60

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Work Protective Gear to Enhance Safety and Comfort

Updated Category News Views 209

Revolutionizing Workplace Safety with New Gear Workplace injuries remain a significant concern across various job sites, with issues such as severe cuts and long-lasting knee damage becoming all too common. These challenges not only compromise the well-being of workers but also inflate costs for employers. Many workers often overlook critical personal protective equipment...

Continue Reading
Exploring Innovations in Toxicology at Upcoming ACMT Meeting

Updated Category News Views 380

Innovative Toxicology Research Unveiled at the 2025 ACMT Meeting In an exciting announcement, the American College of Medical Toxicology (ACMT) is gearing up for its 2025 Annual Scientific Meeting and Symposia, set to take place from April 2 to 6 at the Fairmont Hotel in Vancouver. This year promises an inspiring lineup featuring five days filled with groundbreaking...

Continue Reading
ConnectM Technology Solutions' Live Investor Webinar Invitation

Updated Category News Views 77

ConnectM Announces Exclusive Investor Webinar ConnectM Technology Solutions, Inc. (NASDAQ: CNTM), a pioneering technology firm in the electrification economy, is hosting a special investor webinar on March 4, at 4:15 p.m. Eastern Time. This event is a unique opportunity to learn about the company's strategies and insights in a rapidly evolving industry. Discover the...

Continue Reading
Deadline for SelectQuote Investors Approaching Soon

Updated Category News Views 177

Investors Urged to Take Action on SelectQuote Losses Attention investors! If you have experienced financial losses in SelectQuote, now is the time to act. Faruqi & Faruqi, LLP is leading the charge in investigating claims on behalf of investors who may have suffered due to the company's recent developments. Investors are proudly encouraged to reach out if they believe...

Continue Reading
Empowering Girls in Sports: NRPA and Nike's Initiative

Updated Category News Views 486

NRPA and Nike Unite for Gender Equity in Youth Sports The National Recreation and Park Association (NRPA) has joined forces with Nike, highlighting a shared commitment to advancing gender equity in youth sports. This partnership emphasizes the necessity of equitable access to sporting opportunities for all youth, especially girls, to ensure they thrive in their...

Continue Reading